SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S, PITCH Consortium, COVID-19 Genomics UK (COG-UK) Consortium, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC. · 2022

Read SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. by Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S, PITCH Consortium, COVID-19 Genomics UK (COG-UK) Consortium, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9352574.txt.

Introduction

Willett and co-authors show that Omicron both escapes immunity and enters cells by a new route. Omicron BA.1 and BA.2 carry heavy spike changes, half in the receptor-binding region. The team tested blood from people given three different vaccines. Real-world vaccine performance data were checked alongside.

Both Omicron branches strongly evaded neutralization in the lab. Real-world protection fell too, though boosters partly restored it. Unlike earlier variants, Omicron did not fuse cells into syncytia. It preferred an endosomal entry path that skips the TMPRSS2 route. The fusion flaw mapped to the binding region; the entry shift mapped to the S2 part. The authors link these twin changes to Omicron's fast spread. They may also explain its altered disease pattern.

Catalog record

CREATORWillett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S, PITCH Consortium, COVID-19 Genomics UK (COG-UK) Consortium, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE109 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9352574

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway By Brian J Willett, Joe Grove, Oscar A MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan, Shirin Ashraf, Maria Manali, Agnieszka Szemiel Published in: Nature Microbiology DOI: 10.1038/s41564-022-01143-7 ABSTRACT Abstract Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant. Subject terms: Molecular biology, Immunology, Viral infection, Vaccines MAIN Vaccination against SARS-CoV-2 is based primarily on vaccines that induce immunity to the spike glycoprotein. These vaccines have become the cornerstone of the global public health response to SARS-CoV-21. However, their effectiveness is now being threatened by the emergence of variants of concern (VOC) displaying enhanced transmissibility and evasion of host immunity2. Of the five VOCs that have emerged, the Beta (B.1.351) and Gamma (P.1) variants were primarily associated with immune evasion, spreading internationally but never dominating globally. In contrast, the Alpha (B.1.1.7) and Delta (B.1.617.2) VOCs spread globally and were responsible for notable waves of infections and an increase in reproduction number (R0). The Alpha and Delta variants harbour mutations within the polybasic cleavage site in spike (an H681 in Alpha and R681 in Delta) that enhance cleavage by furin—changes that are associated with enhanced cell entry and may contribute to increased transmissibility. While the Alpha variant spread rapidly, it was in turn replaced by the Delta variant that combined augmented transmissibility with immune evasion2–5. Omicron (lineage B.1.1.529) is the fifth variant to be named as a VOC by the World Health Organization (WHO) and was first detected in mid-November 2021 in Botswana, South Africa6 and in quarantined travellers in Hong Kong7. It has since split into three divergent sub-lineages (BA.1, BA.2 and BA.3) of which BA.1 and BA.2 now dominate worldwide. Emerging data indicate that the Omicron variant evades neutralization by sera obtained from people vaccinated with 1 or 2 doses of vaccine, especially when antibody titres are waning. Indicative studies have shown that 3 doses of spike-based vaccines may provide only partial protection from infection with this variant. Immune evasion by Omicron may have contributed to the extremely high transmission rates in countries with high vaccination rates or natural immunity (R0 of 3–5 in the UK)8–18. In this study, we investigate the antigenic and biological properties of the Omicron variant that might underlie immune evasion and increased transmission of the virus using in vitro assays and real-life population data. RESULTS Omicron displays substantial changes within spike predicted to affect antigenicity and furin cleavage Omicron is characterized by multiple changes within the receptor-binding domain (RBD) of the spike glycoprotein—regions targeted by class 1, 2 and 3 RBD-directed antibodies—and within the N-terminal domain (NTD) supersite (Fig. 1a). Within the spike protein, BA.1 and BA.2 sub-lineages share 21 amino acid mutations with 12 distinct mutations in BA1 and 6 in BA.2. BA.2 lacks the 69,70 deletion present in BA.1. The G339D, N440K, S477N, T478K, Q498R and N501Y mutations (present in BA.1 and BA.2) enhance binding of spike to the human ACE2 receptor, while combinations such as Q498R and N501Y may enhance ACE2 binding additively19. Deep mutational scanning (DMS) estimates at mutated sites are predictive of substantially reduced monoclonal and polyclonal antibody binding and altered binding to human ACE2 (Fig. 1b)20. Fourteen mutations in Omicron (K417N, G446S (BA.1), E484A, Q493R, G496S (BA.1), Q498R and to a lesser extent, G339D, S371L/F (BA.1/BA.2), S373P, N440K, S477N, T478K, N501Y and Y505H) may affect antibody binding on the basis of a calculated escape fraction (a quantitative measure of the extent to which a mutation reduces polyclonal antibody binding by DMS). Seven Omicron RBD mutations (K417N, G446S(BA.1), E484A, Q493R, G496S(BA.1), Q498R and N501Y) have been previously shown to be associated with decreased antibody binding, importantly falling in epitopes corresponding to three major classes of RBD-specific neutralizing antibodies (nAbs). The mutations present in spike also involve key structural epitopes targeted by several monoclonal antibodies in current clinical use. Of these, bamlanivimab, cilgavimab, casirivimab, etesevimab, imdevimab, regdanvimab and tixagevimab bind to the receptor binding motif, and neutralization of Omicron has been shown to be negligible or absent. In contrast, sotrovimab targets a conserved epitope common to SARS-CoV-1 and SARS-CoV-2 that is outside the receptor binding motif, and has only a small reduction (3×) in neutralization potency in BA.121–23. N679K and P681H mutations at the furin cleavage site are predicted individually to increase furin cleavage, although the combination of these changes and an adjacent change (H655Y, also present in the Gamma VOC) in the vicinity of the cleavage site is unknown24. [Figure: Spike amino acid changes, phylogeny and emergence of the Omicron variant.a, Spike homotrimer in open conformation with locations of Omicron substitutions, deletions (Δ) or insertions (ins) present in the lineages BA.1 and BA.2 (superscripts 1,2). Mutated residues highlighted as spheres with opaque surface representation. Residues impacting RBD-specific antibodies of classes 1, 2 or 391; belonging to the NTD antibody supersite (NTD SS)26; or comprising the furin-cleavage site, are coloured, the remainder in grey. Inset shows the wider extent of these sites, with remaining areas of the protein shaded to show the three monomers. Mutations are annotated on the monomer with an ‘up’ receptor-binding domain with D614G (italicized), which is shared by common descent by all lineage B.1 descendants. Visualization uses a complete spike model84 based on a partial cryo-EM structure (RCSB Protein Data Bank (PDB) ID: 6VSB92). b, Heat maps showing properties of amino acid residues in the Omicron variants BA.1 and BA.2. Structure-based epitope scores87 for residues in the spike structure in closed and open conformations are shown. For RBD residues, DMS studies show the escape fraction (quantitative measure of the extent to which a mutation reduced polyclonal antibody binding) for each mutant-averaged (‘plasma average’) and most sensitive plasma (‘plasma max’)20. Each mutation is classified as having mutations affecting neutralization by either monoclonal antibodies (mAbs)27,85,93,94,95 or antibodies in convalescent plasma (infected or vaccinated20,85,95,96). Membership of the furin cleavage site is shown. Distance to ACE2-contacting residues forming the receptor-binding site (RBS) is shown (‘RBS’ is residues with an atom <4 Å of an ACE2 atom in the structure of RBD bound to ACE2) (RCSB PDB ID: 6M0J86). ACE2 binding scores represent the binding constant (Δlog10 KD) relative to the wild-type reference amino acid from DMS experiments97. c, Inferred evolutionary relationships of SARS-CoV-2 from

Read the complete text